The Claim
Weekly administration of 1.0 mg semaglutide reduces the annual decline in estimated glomerular filtration rate by 1.16 mL/min/1.73m² compared to placebo in adults with type 2 diabetes and chronic kidney disease, with statistical significance (P<0.001).
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with type 2 diabetes and chronic kidney disease, a weekly 1.0 mg dose of semaglutide slows the yearly loss of kidney function by 1.16 mL/min/1.73m² compared to a placebo.
See the scientific wording
In adults with type 2 diabetes and chronic kidney disease, weekly administration of 1.0 mg semaglutide slows the annual decline in estimated glomerular filtration rate by 1.16 mL/min/1.73m² compared to placebo (P<0.001), indicating a direct protective effect on kidney function over time.
Semaglutide lowers the amount of sugar the kidneys reabsorb, which reduces the extra workload on the filtering units and decreases swelling and damage in the surrounding kidney tissue, preserving their ability to clean the blood.
What the research says
1 studyStudy: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
In people with type 2 diabetes and kidney disease, taking a weekly shot of semaglutide helped their kidneys filter blood better over time compared to those who didn’t take it — slowing down the loss of kidney function by about 1.2 points per year.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.